FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385680691> ?p ?o ?g. }

• W4385680691 endingPage "394" @default.
• W4385680691 startingPage "388" @default.
• W4385680691 abstract "Objective: To analyze the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treating T lymphoblastic leukemia/lymphoma (T-ALL/LBL) . Methods: This study retrospectively evaluated 119 adolescent and adult patients with T-ALL/LBL from January 2006 to January 2020 at Peking University Third Hospital and Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Patients were divided into chemotherapy-only, chemotherapy followed by allo-HSCT, and chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) groups according to the consolidation regimen, and the 5-year overall survival (OS) and progression-free survival (PFS) rates of each group were compared. Results: Among 113 patients with effective follow-up, 96 (84.9%) patients achieved overall response (ORR), with 79 (69.9%) having complete response (CR) and 17 (15.0%) having partial response (PR), until July 2022. The analysis of the 96 ORR population revealed that patients without transplantation demonstrated poorer outcomes compared with the allo-HSCT group (5-year OS: 11.4% vs 55.6%, P=0.001; 5-year PFS: 8.9% vs 54.2%, P<0.001). No difference was found in 5-year OS and 5-year PFS between the allo-HSCT and auto-HSCT groups (P=0.271, P=0.197). The same results were achieved in the CR population. Allo-HSCT got better 5-year OS (37.5% vs 0) for the 17 PR cases (P=0.064). Different donor sources did not affect 5-year OS, with sibling of 61.1% vs hap-haploidentical of 63.6% vs unrelated donor of 50.0% (P>0.05). No significant difference was found in the treatment response in the early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP) and non-ETP populations. The ETP group demonstrated lower 5-year OS compared with the non-ETP group in the chemotherapy alone group (0 vs 12.6%, P=0.045), whereas no significant difference was found between the ETP and non-ETP groups in the allo-HSCT group (75.0% vs 62.9%, P=0.852). Multivariate analysis revealed that high serum lactate dehydrogenase level, without transplantation, and no CR after chemotherapy induction were independently associated with inferior outcomes (P<0.05) . Conclusion: Allo-HSCT could be an effective consolidation therapy for adult and adolescent patients with T-ALL/LBL. Different donor sources did not affect survival. Allo-HSCT may overcome the adverse influence of ETP-ALL/LBL on OS.目的： 探讨T淋巴母细胞白血病/淋巴瘤（T-ALL/LBL）采用异基因造血干细胞移植（allo-HSCT）作为巩固治疗的疗效及预后因素。 方法： 收集2006年1月至2020年1月北京大学第三医院血液科和中国医学科学院血液病医院收治的119例T-ALL/LBL患者的临床资料。根据巩固治疗方案将患者分为单纯化疗组、化疗序贯异基因造血干细胞移植（allo-HSCT）组、化疗序贯自体造血干细胞移植（auto-HSCT）组，比较各组的5年总生存（OS）率、无进展生存（PFS）率。 结果： 有效随访的113例患者中，79例（69.9%）诱导治疗后达完全缓解（CR）, 17例（15.0%）达部分缓解（PR），治疗总反应率（ORR）达84.9%。诱导治疗获得CR或PR的患者中，化疗序贯allo-HSCT组较单纯化疗组具有更高的5年OS率（55.6%对11.4%，P=0.001）和5年PFS率（54.2%对8.9%，P<0.001），而化疗序贯allo-HSCT组与化疗序贯auto-HSCT组比较5年OS率及5年PFS率差异均无统计学意义（P=0.271，P=0.197）。对获得CR的患者进行分析得出同样结论。在仅获得PR患者中，化疗序贯allo-HSCT组仍然较单纯化疗组显示出生存优势（5年OS率分别为37.5%和0，P=0.064）。不同供者来源的allo-HSCT患者5年OS率差异无统计学意义（同胞全相合移植、单倍体移植、无关供者移植分别为61.1%、63.6%和50.0%，P>0.05）。早期前体T淋巴细胞白血病（ETP-ALL）患者的诱导化疗缓解率和非ETP-ALL患者比较差异无统计学意义，单纯化疗组中ETP-ALL患者较非ETP-ALL患者5年OS率更低（0对12.6%，P=0.045），而在进行allo-HSCT的患者中，ETP-ALL患者与非ETP-ALL患者5年OS率差异无统计学意义（75.0%对62.9%，P=0.852）。诱导治疗未达CR、巩固治疗未采用移植、LDH≥2倍正常值上限为独立预后不良因素（P值均<0.05）。 结论： allo-HSCT可改善T-ALL/LBL患者预后，无论是对诱导治疗达CR还是PR患者，均可作为有效的巩固治疗方法。供者来源不影响allo-HSCT患者长期生存率，allo-HSCT作为巩固治疗手段可以克服ETP-ALL/LBL的不良预后。." @default.
• W4385680691 created "2023-08-09" @default.
• W4385680691 creator A5017214725 @default.
• W4385680691 creator A5023378337 @default.
• W4385680691 creator A5027220663 @default.
• W4385680691 creator A5035591504 @default.
• W4385680691 creator A5048841778 @default.
• W4385680691 creator A5062384242 @default.
• W4385680691 creator A5069331520 @default.
• W4385680691 creator A5089850088 @default.
• W4385680691 date "2023-05-14" @default.
• W4385680691 modified "2023-09-23" @default.
• W4385680691 title "[Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma]." @default.
• W4385680691 cites W133289461 @default.
• W4385680691 cites W1786157004 @default.
• W4385680691 cites W1847661419 @default.
• W4385680691 cites W1971840752 @default.
• W4385680691 cites W1991626056 @default.
• W4385680691 cites W2024279934 @default.
• W4385680691 cites W2065077038 @default.
• W4385680691 cites W2089034243 @default.
• W4385680691 cites W2097501739 @default.
• W4385680691 cites W2104165703 @default.
• W4385680691 cites W2136334054 @default.
• W4385680691 cites W2141819662 @default.
• W4385680691 cites W2215516645 @default.
• W4385680691 cites W2310716991 @default.
• W4385680691 cites W2316981979 @default.
• W4385680691 cites W2336673742 @default.
• W4385680691 cites W234352621 @default.
• W4385680691 cites W2474989309 @default.
• W4385680691 cites W2837193188 @default.
• W4385680691 cites W4211217280 @default.
• W4385680691 cites W2118661946 @default.
• W4385680691 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2023.05.006" @default.
• W4385680691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37550188" @default.
• W4385680691 hasPublicationYear "2023" @default.
• W4385680691 type Work @default.
• W4385680691 citedByCount "0" @default.
• W4385680691 crossrefType "journal-article" @default.
• W4385680691 hasAuthorship W4385680691A5017214725 @default.
• W4385680691 hasAuthorship W4385680691A5023378337 @default.
• W4385680691 hasAuthorship W4385680691A5027220663 @default.
• W4385680691 hasAuthorship W4385680691A5035591504 @default.
• W4385680691 hasAuthorship W4385680691A5048841778 @default.
• W4385680691 hasAuthorship W4385680691A5062384242 @default.
• W4385680691 hasAuthorship W4385680691A5069331520 @default.
• W4385680691 hasAuthorship W4385680691A5089850088 @default.
• W4385680691 hasConcept C126322002 @default.
• W4385680691 hasConcept C143998085 @default.
• W4385680691 hasConcept C194409129 @default.
• W4385680691 hasConcept C203014093 @default.
• W4385680691 hasConcept C2776090121 @default.
• W4385680691 hasConcept C2776694085 @default.
• W4385680691 hasConcept C2777408962 @default.
• W4385680691 hasConcept C2777478502 @default.
• W4385680691 hasConcept C2779338263 @default.
• W4385680691 hasConcept C2781413609 @default.
• W4385680691 hasConcept C2908647359 @default.
• W4385680691 hasConcept C2911091166 @default.
• W4385680691 hasConcept C71924100 @default.
• W4385680691 hasConcept C8891405 @default.
• W4385680691 hasConcept C90924648 @default.
• W4385680691 hasConcept C99454951 @default.
• W4385680691 hasConceptScore W4385680691C126322002 @default.
• W4385680691 hasConceptScore W4385680691C143998085 @default.
• W4385680691 hasConceptScore W4385680691C194409129 @default.
• W4385680691 hasConceptScore W4385680691C203014093 @default.
• W4385680691 hasConceptScore W4385680691C2776090121 @default.
• W4385680691 hasConceptScore W4385680691C2776694085 @default.
• W4385680691 hasConceptScore W4385680691C2777408962 @default.
• W4385680691 hasConceptScore W4385680691C2777478502 @default.
• W4385680691 hasConceptScore W4385680691C2779338263 @default.
• W4385680691 hasConceptScore W4385680691C2781413609 @default.
• W4385680691 hasConceptScore W4385680691C2908647359 @default.
• W4385680691 hasConceptScore W4385680691C2911091166 @default.
• W4385680691 hasConceptScore W4385680691C71924100 @default.
• W4385680691 hasConceptScore W4385680691C8891405 @default.
• W4385680691 hasConceptScore W4385680691C90924648 @default.
• W4385680691 hasConceptScore W4385680691C99454951 @default.
• W4385680691 hasIssue "5" @default.
• W4385680691 hasLocation W43856806911 @default.
• W4385680691 hasOpenAccess W4385680691 @default.
• W4385680691 hasPrimaryLocation W43856806911 @default.
• W4385680691 hasRelatedWork W1984282923 @default.
• W4385680691 hasRelatedWork W2089034243 @default.
• W4385680691 hasRelatedWork W2091720821 @default.
• W4385680691 hasRelatedWork W2373226427 @default.
• W4385680691 hasRelatedWork W2387456186 @default.
• W4385680691 hasRelatedWork W2388730008 @default.
• W4385680691 hasRelatedWork W3031018394 @default.
• W4385680691 hasRelatedWork W3031808705 @default.
• W4385680691 hasRelatedWork W757206253 @default.
• W4385680691 hasRelatedWork W911446555 @default.
• W4385680691 hasVolume "44" @default.
• W4385680691 isParatext "false" @default.
• W4385680691 isRetracted "false" @default.
• W4385680691 workType "article" @default.